The Global Non-Invasive Prenatal Testing Market was valued at US$ 2.75 billion in 2019 and is expected to surpass US$ 11 billion by 2030 at a CAGR of 16% during 2020 and 2030. The average age of pregnant women has gone up across the globe. This has increased the risk of babies born with genetic abnormalities such as Down Syndrome, Turner Syndrome, Edwards Syndrome and so on. The advent of non-invasive prenatal testing happened to detect such abnormalities in the fetus in a safe manner. The daunting task of identifying possibility of genetic abnormalities is made possible through a simple blood test, hence non-invasive in nature. Along with being non-invasive this technique delivers accurate results. The test is a simple blood test and can be successfully conducted as early as first trimester of pregnancy. The changing lifestyle across masses has led to an increased count of genetic abnormalities in babies born worldwide. Lack of care during pregnancy might also lead to such irreversible abnormalities in new born kids. The evolution of technology has encouraged the users to choose non-invasive prenatal testing technique to get necessary tests in advance.
